VivaZome and BIA Separations to collaborate on downstream technology for exosome purification
21 December 2020; Melbourne Australia and Ajdovščina, Slovenia: VivaZome Therapeutics Pty Ltd (“VivaZome”) and BIA Separations (“BIA”) – a part of the life science group Sartorius – today announced that they have entered into a collaborative research project for exosome purification. BIA’s unique CIM (Convective Interaction Media) monolith chromatography technology will be used to purify exosomes from VivaZome’s cell cultures, with the aim of developing a high-efficiency downstream purification and concentration process for exosome production.
Under the collaborative arrangement, VivaZome will provide exosome-rich, cell culture supernatant produced by VivaZome’s preferred cell type. BIA’s expert Bioprocessing Team, located in Ajdovščina, Slovenia, will use the VivaZome material to evaluate and optimise the monolith technology with the objective of demonstrating high purification capability, efficient removal of contaminants, fast flow rates and scale-ability. VivaZome and BIA will each contribute their expertise in exosome characterisation and analytics.
VivaZome’s Chief Executive Officer, Dr David Haylock, stated: “VivaZome is delighted to enter into this international collaboration. BIA brings high-level expertise and unique technology to the table. The monolith technology has been shown to work well with exosomes and we look forward to building on that experience. BIA and VivaZome recognise that the development of a high-efficiency downstream separation and concentration process is key to the manufacture of therapeutic exosomes and to realising their therapeutic potential.”